Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 142   

Articles published

NVS 100.07 +0.06 (0.06%)
price chart
Stock To Watch : Novartis AG (ADR)(NYSE:NVS)
Novartis AG (ADR)(NYSE:NVS) (TREND ANALYSIS) shares are still trading near the 52-week high of $102.59. The stock closed last trading session at $101.48, with a volume of 1,334,174 shares against an average volume for the last 3 months of 1,498,780.
Novartis AG (ADR) Analyst Rating Update
As many as 8 brokerage firms have rated Novartis AG (ADR) (NYSE:NVS) at 1.75. Research Analysts at Zacks have ranked the company at 3, suggesting the traders with a rating of Neutral.
Novartis AG (ADR), GlaxoSmithKline plc (ADR) Recieve Final Approval For Thee ...
According to the US Federal Trade Commission's (FTC) announcement yesterday, Novartis (NYSE:NVS) has received the US antitrust regulator's approval to acquire drugs from Glaxo's oncology portfolio, contingent upon certain specified conditions.
Novartis AG (ADR) Heart Failure Drug Granted FDA Priority Review
Novartis AG (ADR) (NYSE:NVS), a world leader in the research and development of healthcare products, announced Friday that its novel heart failure drug, LCZ696, has been granted a Priority Review designation by the US Food and Drug Administration ...
Novartis says heart failure medicine LCZ696 granted FDA piority review  Rock Hill Daily
Trade of the Day: Pullback in NVS Stock Could Yield 15%-Plus Profits
Novartis AG (ADR) (NYSE:NVS) - This Switzerland-based health care company is a leading international provider of pharmaceuticals, generic drugs, and consumer and animal health products.
Large Inflow of Money Witnessed in Novartis AG (ADR) Shares  Rock Hill Daily
Novartis AG (ADR) (NVS)'s Cosentyx Gets Clearance In Europe
Novartis AG (ADR) (NYSE:NVS)'s Cosentyx� gets the European Commission approval to be the first-line treatment of moderate-to-severe plaque psoriasis in adults requiring systemic therapy.
Stock Watch: Novartis AG (ADR) (NYSE:NVS), MGIC Investment Corp. (NYSE ...  Realist Investor
Novartis' Cosentyx Approved in Europe for Plaque Psoriasis - Analyst Blog  Nasdaq
Novartis AG (ADR) Receives Average Target Price of $103.5
Novartis AG (ADR) (NYSE:NVS) shares are expected to touch $103.5 in the short term. This short term price target has been shared by 3 analysts.
Investors Sell Novartis AG (ADR) on Price Strength
Novartis AG (ADR) (NYSE:NVS) had an uninteresting session and gained 2.44 points till last call. The price was at $98.93, gaining 2.53% till the last intraday data.
First Call Rating Update on Novartis AG (ADR)  Stafford Daily
Novartis AG (ADR) Earnings Revenue Update  Rock Hill Daily
Analyst Rating Update on Novartis AG (ADR)
Research firm Zacks has rated Novartis Ag (NYSE:NVS) and has ranked it at 4, indicating that for the short term the shares are a sell.
Stock to Follow: Novartis AG (NYSE:NVS)
[BizJournals] Novartis AG (ADR) (NYSE:NVS) moved a step closer to finalizing a blockbuster deal with GlaxoSmithKline that will consolidate product lines at the two powerhouse pharmaceutical giants.